• news.cision.com/
  • PainDrainer/
  • Paindrainer´s clinical multi-center study shows remarkable positive improvements for chronic pain patients

Paindrainer´s clinical multi-center study shows remarkable positive improvements for chronic pain patients

Report this content

MEDICON VILLAGE, LUND, SWEDEN – Paindrainer AB announces the publication of its pivotal multi-center study in the well-respected journal Pain Medicine. The study clearly demonstrates that self-management of chronic pain using Paindrainer´s digital tool, powered by a proprietary neural network, significantly improved subjects’ pain interference, physical function, depression, anxiety, and pain catastrophizing over the 12-week study period.

The pivotal multi-center study conducted with Newton-Wellesley Hospital and Weill Cornell Medicine was successfully completed and published in the leading pain magazine Pain Medicine. The outcome was successful regarding both primary and secondary outcomes, demonstrating an improvement in the majority of patient for all measured parameters, including quality of life.

Neel Mehta MD, senior author of the publication and Division Chief of Pain Management at Weill Cornell Medicine says, “We were able to demonstrate a first-of-its kind, patient-centric digital tool to help chronic pain sufferers understand what works best for their own pain journey. Rather than relying on non-specific population data, the tool let patients guide their own path to improved pain relief.

Chronic pain is a pervasive and debilitating condition that affects millions of people worldwide. Patients with chronic pain often struggle to find effective methods to control their pain and improve their quality of life and physical function. Paindrainer® was developed to address this critical need by providing patients with a comprehensive digital tool to help them manage their pain and improve their overall well-being.

“This important study represents a major milestone for our company and demonstrates the unique clinical effects of our AI-powered medical device. The findings provide compelling evidence of the efficacy of our digital tool and underscore its potential to transform the lives for patients struggling with chronic pain”, says Erik Frick CEO Paindrainer AB.

Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. The Paindrainer app is the first evidence based digital tool demonstrating improved quality of life in patients suffering from chronic pain. The solution is powered by a proprietary Artificial Neural Network (ANN) and is fully adaptive to each patient, a feature called 360o patient-centricity©.

“We look forward to continuing our work to improve the lives of chronic pain patients and to advance the field of pain management.”, continues Erik Frick CEO.  

Link to the Abstract Pain Medicine:  

https://pubmed.ncbi.nlm.nih.gov/37104747

An artificial intelligence-powered, patient-centric digital tool for self-management of chronic pain: A prospective, multicenter clinical trial - PubMed (nih.gov)

For more information, please contact:
Erik Frick, CEO

Paindrainer AB
erik.frick@paindrainer.com
+46 736 612123

About Paindrainer AB
Paindrainer AB is a company developing digital platforms and applications contributing to health and well-being. The company was founded in 2018 by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement, and Göran Barkfors (IT specialist). The idea was born when Maria, after participating in several pain rehabilitation programs, realized that the pain is affected by more factors than the human brain can keep track of, since all days are different. The Paindrainer® app uses advanced calculations based on artificial intelligence to coach the user in planning their day not to exceed a certain pain level, and to ensure that there is energy left for activities highly valued.

Paindrainer® has clinical evidence, is based on Acceptance and Commitment Therapy (ACT), self-management and artificial intelligence (AI). The app is CE Class 1 Medical Device.

www.paindrainer.com

Subscribe